Clinical trial
A Collaborative Double-Blind Placebo-Controlled Trial of Intravenous Ribavirin…
NCT00001123 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00001123 |
|---|---|
| Title | A Collaborative Double-Blind Placebo-Controlled Trial of Intravenous Ribavirin As a Treatment for Presumed Hantavirus Pulmonary Syndrome |
| Official title | A Collaborative Double-Blind Placebo-Controlled Trial of Intravenous Ribavirin As a Treatment for Presumed Hantavirus Pulmonary Syndrome |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Study type | Interventional |
| Conditions | Hantavirus Pulmonary Syndrome |
| Intervention type | Drug |
| Interventions | Ribavirin |
| Enrollment | 130 |
| Completion | Nov 1, 2005 |
| First posted | Aug 31, 2001 |
| Last update posted | Aug 27, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: